Interní Med. 2008; 10(1): 26-30

Rationale antibiotic therapy with a focus on the newest antibiotic

doc. MUDr. Václav. Dostál
Oblastní nemocnice Jičín, LDN Nový Bydžov

Global situation forces experts to think about worsening situation in the efficacy of antimicrobial therapy. Antibiotic resistance increases in hospital and community pathogens both in systemic and local antibiotics. It is an interdisciplinary problem. An inappropriate antibiotic therapy causes a risk of antimicrobial resistance, drug toxicity and other complications of therapy. A preservation of antibiotic efficacy in future is determined by a rationale approach o anti-infective therapy and requires with a small number of exceptions a thorough patient examination. A team of specialists with a leading role of infectious diseases specialist should participate in the choice of antimicrobial therapy. The need for new antibiotic is necessary; their use however should be prudent. It is necessary to recommend their use only in selected situations. In most situations it is enough to use the current spectrum of medications, both in monotherapy or combinations. The paper reviews some of new antibiotics and their indications in infections caused by „problematic“ bacteria.

Keywords: new antibiotics, antibiotic resistance, empirical treatment, „problem“ bacteria, antibiotic policy

Published: April 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Dostál DMV. Rationale antibiotic therapy with a focus on the newest antibiotic. Interní Med. 2008;10(1):26-30.
Download citation

References

  1. Bal AM, Gould IA. Empirical antimicrobial treatment for chemotherapy-induced Febrile Neutropenia. Int J Antimicrob Agents 2007; 29: 501-509. Go to original source... Go to PubMed...
  2. Ben-Ami R, Giladi M, Carmeli Y, et al. Hospital-acquired infective endokarditis: should be definition be broadened? Clin Infect Dis 2004; 38: 843-850. Go to original source... Go to PubMed...
  3. Bogdanovich T, Ednie LM, Shapiro S, Appelbaum PC. Antistaphylococcal aktivity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother 2006; 50: 2050-2057. Go to original source... Go to PubMed...
  4. Brink AJ, Feldman C, Grolman DW, et al. Appropriate use of the carbapenems. S Afr Med J.2004; 94: 857-861.
  5. Davies TA, Slang W, Bush K. Activities of Ceftobiprole and Other ?-Lactams against Streptococcus pneumonie Clinical Isolates from the United States with Defined Substitutions in Penicilin-Binding Proteins PBP 1a, PBP 2b, and PBP 2x. Antimicrob Agents Chemother 2006; 50: 2530-2532. Go to original source... Go to PubMed...
  6. Dellit TH. Antimicrobial stewardship guidelines. Clin Infect Dis 2007; 44: 159-177. Go to original source... Go to PubMed...
  7. Dostál V. Racionální antibiotická terapie. In Dostál V. a kol. Infektologie. Karolinum Praha 2004: 47-62.
  8. Enoch DA, Bygott JA, Daly M-L, Karas JA. Daptomycin. J Infection 2007; 55: 205-213. Go to original source... Go to PubMed...
  9. Esposito S, Leone S. Antimicrobial treatment for Intensive Care Unit (ICU) infections including the role of the infectious disease specialist. Int J Antimicrob Agents 2007; 29: 494-500. Go to original source... Go to PubMed...
  10. Falagas ME, Giannopoulou KP, Ntziora F, Papagelopoulos PJ. Daptomycin for treatment of patiens with bone and point infections: a systematic review of the clinical evidence. Int J Antimicrob Agents 2007; 30: 202-209. Go to original source... Go to PubMed...
  11. Fowler VG, Jr, Boucher HW, Corey GF, et all. Daptomycin versus standard therapy for bacteremia and edocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355: 653-665. Go to original source... Go to PubMed...
  12. Hanson ND. AmpC ?-lactamases: What do we need to know for the future? J Antimicrob Chemother 2003; 52: 2-4. Go to original source... Go to PubMed...
  13. Chen AY, Zervos MJ, Vazquez JA. Dalbavancin: A novel antimicrobial. Int J Clin Pract 2007; 61: 853-863. Go to original source... Go to PubMed...
  14. Kern WV. Daptomycin: first in a new class of antibiotics for complicated skin and soft-tissue infections. Int J Clin Pract 2006; 60: 370-378 D1-3. Go to original source... Go to PubMed...
  15. Meka VG, Pillai SK, Sakoulas G, et al. Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of single copy of rRNA. J Infect Dis 2004; 190: 311-317, T1-7. Go to original source... Go to PubMed...
  16. Nathwani D. Tigecycline: clinical evidence and formulary positioning. Int J Antimicrob Agents 2005; 25: 185-192. Go to original source... Go to PubMed...
  17. Ntziora F, Falagas ME. Linezolid for the treatment of patients with central nervous system infection. Ann Pharmacother 2007; 41: 296-308. Go to original source... Go to PubMed...
  18. Rittenhouse S, Biswas S, Broskev J, et al. Selection of retapamulin, a novel pleuromutilin for topical use. Antimicrob Agents Chemother 2006; 50: 3882-3885. Go to original source... Go to PubMed...
  19. Sykes RB, Matthew M. The ?-lactamases of gramnegative bacteria and their role in resistance to ?-lactam antibiotics. J Antimicrob Chemother 1976; 2: 115-157. Go to original source... Go to PubMed...
  20. Wenzel RP. The antibiotic pipeline-challenges, costs, and values. N Engl J Med 2004; 351: 523-526. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.